Browse evidence-based analysis of health-related claims and assertions
Log in to see full claim details, scientific mechanisms, and cited studies.
In people with obesity and prediabetes, a drug called sitagliptin increases certain gut hormones but does not improve how the body responds to insulin or lower fasting blood sugar. This suggests that...
Blocking the GLP-1 receptor with exendin(9-39) eliminates the improvements in insulin sensitivity and blood glucose control that result from liraglutide treatment in people with obesity and...
In people with obesity and prediabetes, the drug liraglutide lowers blood glucose levels after fasting and after meals within two weeks, even without weight loss. This effect is not seen with other...
In people with obesity and prediabetes, a daily dose of liraglutide improves how the body responds to insulin within two weeks, before any significant weight loss occurs, and this improvement is...
In adults with type 2 diabetes and heart disease, the rates of severe low blood sugar and pancreatitis are about the same for tirzepatide and dulaglutide, meaning neither drug appears to cause more...
In adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide is linked to slightly higher rates of nausea, vomiting, and diarrhea compared to dulaglutide, but serious side...
Over 36 months, tirzepatide lowered body weight and blood sugar levels more than dulaglutide in adults with type 2 diabetes and heart disease, while both drugs had similar effects on cardiovascular...
Among adults with type 2 diabetes and heart disease, tirzepatide was associated with a 16% lower risk of death from any cause over four years compared to dulaglutide, based on statistical analysis of...
In adults with type 2 diabetes and heart disease, a weekly injection of tirzepatide reduces the risk of heart-related death, heart attack, or stroke just as effectively as another drug called...
In adults with type 2 diabetes and existing heart disease, tirzepatide and dulaglutide show similar rates of stroke over nearly four years of follow-up, with no statistically significant difference...
In adults with type 2 diabetes and existing heart disease, tirzepatide is associated with a lower rate of procedures to reopen blocked heart arteries compared to dulaglutide, based on a study...
In adults with type 2 diabetes and heart disease, tirzepatide is associated with a 16% lower risk of death from any cause over about four years compared to dulaglutide.
In adults with type 2 diabetes and cardiovascular disease, tirzepatide lowers the combined risk of serious kidney outcomes—including worsening protein in the urine, significant decline in kidney...
In adults with type 2 diabetes and heart disease, a weekly injection of tirzepatide lowers the risk of serious heart and kidney events—such as heart attack, stroke, hospitalization for heart failure,...
Current high-quality research does not show that GLP-1 receptor agonists slow down the physical deterioration of joints in osteoarthritis, such as loss of cartilage or narrowing of joint space, even...
Medications called GLP-1 receptor agonists lower levels of certain inflammation markers in people with type 2 diabetes, but there is no evidence that this reduction leads to better symptoms or...
In people with type 2 diabetes, GLP-1 receptor agonists are linked to a modest increase in flare-ups of rheumatoid arthritis, but it is not known whether this is due to the drug directly affecting...
In people with type 2 diabetes, starting GLP-1 receptor agonists is linked to a slightly higher rate of being newly diagnosed with osteoarthritis, but it is unclear whether this is because weight...
In obese adults with knee osteoarthritis, a weekly injection of semaglutide for over a year reduces knee pain significantly more than a placebo, mostly because of weight loss, but it does not appear...
In people with type 2 diabetes, GLP-1 receptor agonists are linked to a higher chance of gout flare-ups, probably because rapid weight loss releases stored uric acid into the bloodstream, requiring...
Medications that activate GLP-1 receptors are associated with lower urges to eat high-calorie foods and reduced persistent thoughts about food in people.
Activating the glucagon receptor in humans leads to higher energy expenditure at rest and a faster heart rate while at rest.
Medications called GLP-1 receptor agonists are associated with a reduction in the number of calories consumed each day by 16% to 39% in human individuals.
GLP-1 receptor agonists trigger changes in the body that occur even when weight loss is accounted for, suggesting these drugs have effects beyond reducing body weight.